Juvenile dermatomyositis

Current Rheumatology Reports

Volumn 13, Issue 3, 2011, Pages 216-224

  Batthish, Michelle ^a   Feldman, Brian M ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical course; Clinical features; Epidemiology; Juvenile dermatomyositis; Outcome measures; Pathogenesis; Treatment

Indexed keywords

CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISONE; RITUXIMAB; TACROLIMUS;

AMYOPATHIC JUVENILE DERMATOMYOSITIS; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; CALCINOSIS; CLINICAL FEATURE; CONTRACTURE; DIAGNOSTIC PROCEDURE; DISEASE CONTROL; DISEASE COURSE; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; GASTROINTESTINAL DISEASE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; JUVENILE DERMATOMYOSITIS; LIPODYSTROPHY; LUNG DISEASE; MUSCLE TISSUE; MUSCLE WEAKNESS; PATHOGENESIS; PROGNOSIS; RASH; SINGLE DRUG DOSE; TREATMENT RESPONSE; VASCULAR DISEASE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; DERMATOMYOSITIS; DISEASE PROGRESSION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; PROGNOSIS; TREATMENT OUTCOME;

EID: 79957477082     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0167-9     Document Type: Article

References (58)

1. LJ McCann, et al. 2006 The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)-clinical characteristics of children recruited within the first 5 yr Rheumatology (Oxford) 45 10 1255 1260 10.1093/ rheumatology/kel099 1:STN:280:DC%2BD28rmvFWltQ%3D%3D (Pubitemid 44542066)
2. DP Symmons JA Sills SM Davis 1995 The incidence of juvenile dermatomyositis: results from a nation-wide study Br J Rheumatol 34 8 732 736 7551657 10.1093/rheumatology/34.8.732 1:STN:280:DyaK28%2FjsF2itQ%3D%3D
3. EP Mendez, et al. 2003 US incidence of juvenile dermatomyositis, 1995-1998: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Registry Arthritis Rheum 49 3 300 305 12794783 10.1002/art.11122 (Pubitemid 36682395)
4. S Compeyrot-Lacassagne BM Feldman 2005 Inflammatory myopathies in children Pediatr Clin North Am 52 2 493 520 15820377 10.1016/j.pcl.2005.01.004 vi-vii (Pubitemid 40463664)
5. AV Ramanan BM Feldman 2002 Clinical features and outcomes of juvenile dermatomyositis and other childhood onset myositis syndromes Rheum Dis Clin North Am 28 4 833 857 12506775 10.1016/S0889-857X(02)00024-8 1:STN:280:DC%2BD3s%2FgtFWgsg%3D%3D (Pubitemid 36008555)
6. AM Reed L Pachman C Ober 1991 Molecular genetic studies of major histocompatibility complex genes in children with juvenile dermatomyositis: increased risk associated with HLA-DQA1*0501 Hum Immunol 32 4 235 240 1783570 10.1016/0198-8859(91)90085-N 1:CAS:528:DyaK38Xht1Klu7w%3D
7. G Mamyrova, et al. 2006 Immunogenetic risk and protective factors for juvenile dermatomyositis in Caucasians Arthritis Rheum 54 12 3979 3987 17133612 10.1002/art.22216 1:CAS:528:DC%2BD2sXktlaksg%3D%3D (Pubitemid 44955902)
8. LM Pachman, et al. 1977 Increased frequency of HLA-B8 in juvenile dermatomyositis Lancet 2 8050 1238 73944 10.1016/S0140-6736(77)90487-1 1:STN:280:DyaE1c%2FntVKrug%3D%3D
9. LM Pachman, et al. 2000 TNFalpha-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor alpha, disease duration, and pathologic calcifications Arthritis Rheum 43 10 2368 2377 11037898 10.1002/1529-0131(200010)43:10<2368::AID-ANR26>3.0.CO;2-8 1:CAS:528:DC%2BD3cXnslWjsLY%3D
10. LG Rider, et al. 2000 Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies Clin Exp Immunol 121 1 47 52 10886238 10.1046/j.1365-2249.2000.01266.x 1:CAS:528:DC%2BD3cXltlKltLs%3D (Pubitemid 30436014)
11. M Massa, et al. 2002 Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis Arthritis Rheum 46 11 3015 3025 12428245 10.1002/art.10566 1:CAS:528:DC%2BD38XptlSks7g%3D (Pubitemid 35315896)
12. LM Pachman, et al. 2005 History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry Arthritis Rheum 53 2 166 172 15818654 10.1002/art.21068 (Pubitemid 40530155)
13. C Manlhiot, et al. 2008 Assessment of an infectious disease history preceding juvenile dermatomyositis symptom onset Rheumatology (Oxford) 47 4 526 529 10.1093/rheumatology/ken038 1:STN:280:DC%2BD1c7ps1Ojuw%3D%3D
14. Khanna S, Reed AM. Immunopathogenesis of juvenile dermatomyositis. Muscle Nerve. 2010;41(5):581-92.
15. CK Li, et al. 2004 MHC Class I overexpression on muscles in early juvenile dermatomyositis J Rheumatol 31 3 605 609 14994413 1:CAS:528: DC%2BD2cXislKrtLY%3D (Pubitemid 38337626)
16. TB Niewold, et al. 2009 Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy Arthritis Rheum 60 6 1815 1824 19479879 10.1002/art.24555 1:CAS:528:DC%2BD1MXotVeqt70%3D This study examined serum IFN-α activity in a cohort of children with JDM to determine relationships between IFN-α and indicators of disease activity and severity. Serum IFN-α activity was associated with higher serum levels of muscle-derived enzymes and a shorter duration of untreated disease in patients with newly diagnosed JDM, and was inversely correlated with measures of chronic disease activity at 36 months after diagnosis
17. Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010;12(3):198-203.
18. H Bilgic, et al. 2009 Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis Arthritis Rheum 60 11 3436 3446 19877033 10.1002/art.24936 1:CAS:528:DC%2BD1MXhsFentLzK This study evaluated the capacity of IFN-dependent peripheral blood gene and chemokine signatures and levels of proinflammatory cytokines to serve as biomarkers for disease activity in adult DM and JDM. Serum IL-6 production and the type 1 IFN gene signature were found to be candidate biomarkers for disease activity in adult DM and JDM
19. A Bohan JB Peter 1975 Polymyositis and dermatomyositis (first of two parts) N Engl J Med 292 7 344 347 1090839 10.1056/NEJM197502132920706 1:STN:280:DyaE2M7hvVyrtA%3D%3D
20. VE Brown, et al. 2006 An international consensus survey of the diagnostic criteria for juvenile dermatomyositis (JDM) Rheumatology (Oxford) 45 8 990 993 10.1093/rheumatology/kel025 1:STN:280:DC%2BD28vjvVelsQ%3D%3D (Pubitemid 44283054)
21. S Tse, et al. 2001 The arthritis of inflammatory childhood myositis syndromes J Rheumatol 28 1 192 197 11196524 1:STN:280:DC%2BD3M7jtFyjtA%3D%3D (Pubitemid 32062045)
22. JD Akikusa, et al. 2005 Eye findings in patients with juvenile dermatomyositis J Rheumatol 32 10 1986 1991 16206356 (Pubitemid 41429030)
23. CD Cook FS Rosen BQ Banker 1963 Dermatomyositis and Focal Scleroderma Pediatr Clin North Am 10 979 1016 14145026 1:STN:280:DyaF2c7gt12mtg%3D%3D
24. Schmeling H, et al. Nailfold capillary density is importantly associated over time with muscle and skin disease activity in juvenile dermatomyositis. Rheumatology (Oxford). 2010. doi: 10.1093/rheumatology/keq407.
25. RL Smith, et al. 2004 Skin involvement in juvenile dermatomyositis is associated with loss of end row nailfold capillary loops J Rheumatol 31 8 1644 1649 15290747 (Pubitemid 39006649)
26. BM Feldman, et al. 1999 Nailfold capillaries as indicators of disease activity in juvenile idiopathic inflammatory myopathies (JIIM) Arthritis Rheum 42 9 S181
27. CH Spencer, et al. 1984 Course of treated juvenile dermatomyositis J Pediatr 105 3 399 408 6470862 10.1016/S0022-3476(84)80012-8 1:STN:280: DyaL2c3ptFyhtw%3D%3D (Pubitemid 14072122)
28. AM Huber, et al. 2000 Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis Arthritis Rheum 43 3 541 549 10728746 10.1002/1529-0131(200003)43:3<541::AID-ANR9>3.0.CO;2-T 1:STN:280:DC%2BD3c7ptFSqsg%3D%3D (Pubitemid 30394944)
29. CE Blane, et al. 1984 Patterns of calcification in childhood dermatomyositis Am J Roentgenol 142 2 397 400 1:STN:280:DyaL2c7isVOksQ%3D%3D (Pubitemid 14182104)
30. SL Bowyer, et al. 1983 Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification J Pediatr 103 6 882 888 6644423 10.1016/S0022-3476(83)80706-9 1:STN:280:DyaL2c%2FmsVShsQ%3D%3D (Pubitemid 14204178)
31. C Huemer, et al. 2001 Lipodystrophy in patients with juvenile dermatomyositis-evaluation of clinical and metabolic abnormalities J Rheumatol 28 3 610 615 11296968 1:CAS:528:DC%2BD3MXisVyqu70%3D (Pubitemid 32202669)
32. KA Rouster-Stevens, et al. 2008 Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis Arthritis Rheum 59 2 222 226 18240180 10.1002/art.23341 1:CAS:528:DC%2BD1cXjt1yqs70%3D (Pubitemid 351272958)
33. LM Pachman N Cooke 1980 Juvenile dermatomyositis: a clinical and immunologic study J Pediatr 96 2 226 234 6965409 10.1016/S0022-3476(80)80807-9 1:STN:280:DyaL3c%2Fps1eksA%3D%3D (Pubitemid 10129401)
34. RL Euwer RD Sontheimer 1993 Amyopathic dermatomyositis: a review J Invest Dermatol 100 1 124S 127S 8423381 10.1111/1523-1747.ep12356896 1:STN:280:DyaK3s7jvFGksA%3D%3D (Pubitemid 23035918)
35. Stringer E, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. J Rheumatol. 2010;37(9):1953-1961. This study assessed the therapeutic approaches of North American pediatric rheumatologists to inform future studies of therapy in JDM. For most North American pediatric rheumatologists, corticosteroids and methotrexate appear to be the standard of care for typical cases of JDM. There is variability, however, in the route of administration of corticosteroids and use of IVIG and hydroxychloroquine.
36. Huber AM, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010;62(2):219-25. This study used JDM survey data and expert opinion to develop a small number of consensus treatment protocols that reflect current initial treatment of moderately severe JDM. Three protocols that described the first 2 months of treatment were developed. All protocols included corticosteroids and methotrexate.
37. AV Ramanan, et al. 2005 The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids Arthritis Rheum 52 11 3570 3578 16255046 10.1002/art.21378 1:CAS:528: DC%2BD2MXht1Krur%2FI (Pubitemid 41612226)
38. R Seshadri, et al. 2008 The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis Arthritis Rheum 59 7 989 995 18576304 10.1002/art.23829 1:CAS:528:DC%2BD1cXpt1egtLc%3D (Pubitemid 351990996)
39. MC Dalakas, et al. 1993 A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis N Engl J Med 329 27 1993 2000 8247075 10.1056/NEJM199312303292704 1:STN:280:DyaK2c%2Fmslalsw%3D%3D (Pubitemid 24015043)
40. EM Pullenayegum, et al. 2008 Fitting marginal structural models: estimating covariate-treatment associations in the reweighted data set can guide model fitting J Clin Epidemiol 61 9 875 881 18486447 10.1016/j.jclinepi.2007. 10.024
41. (PRINTO), P.R.I.N.T.O. Juvenile Dermatomyositis Trial. 2010 cited; Available from: http://www.printo.it/project-ongoing-detail.asp?ProjectID=14.
42. P Riley, et al. 2004 Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety Rheumatology (Oxford) 43 4 491 496 10.1093/rheumatology/keh082 1:CAS:528:DC%2BD2cXitlyhsb0%3D (Pubitemid 38495769)
43. P Riley, et al. 2008 Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis Rheumatology (Oxford) 47 6 877 880 10.1093/rheumatology/ken074 1:CAS:528:DC%2BD1cXmtlentrg%3D (Pubitemid 351796377)
44. MA Cooper, et al. 2007 Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients Arthritis Rheum 56 9 3107 3111 17763414 10.1002/art.22856 1:CAS:528:DC%2BD2sXht1GgtbrN (Pubitemid 47502758)
45. Oddis CV et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM) - The RIM study. Arthritis Rheum. 2010;62(10)Suppl.
46. Rouster-Stevens K. A., et al. Mycophenolate mofetil: A possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(10):1446-51.
47. J Hassan JJ van der Net A van Royen-Kerkhof 2008 Treatment of refractory juvenile dermatomyositis with tacrolimus Clin Rheumatol 27 11 1469 1471 18716733 10.1007/s10067-008-0973-2
48. NY Olson CB Lindsley 1989 Adjunctive use of hydroxychloroquine in childhood dermatomyositis J Rheumatol 16 12 1545 1547 2483176 1:STN:280:DyaK3c7nt1ehtw%3D%3D (Pubitemid 20053192)
49. N Ruperto, et al. 2003 Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis Rheumatology (Oxford) 42 12 1452 1459 10.1093/rheumatology/keg403 (Pubitemid 37508918)
50. FW Miller, et al. 2001 Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies Rheumatology (Oxford) 40 11 1262 1273 10.1093/rheumatology/40.11.1262 1:STN:280:DC%2BD3MnnvFalsw%3D%3D
51. Rider, L.G., et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010;62(4):465-72. This study validated MMT for strength assessment in JDM and adult DM and polymyositis. Consensus was reached to use a subset of eight muscles (neck flexors, deltoids, biceps, wrist extensors, gluteus maximus and medius, quadriceps, and ankle dorsiflexors) that performed as well as the total and proximal MMT, and had good face validity and ease of assessment.
52. AM Huber, et al. 2004 Validation and clinical significance of the Childhood Myositis Assessment Scale for assessment of muscle function in the juvenile idiopathic inflammatory myopathies Arthritis Rheum 50 5 1595 1603 15146430 10.1002/art.20179 (Pubitemid 38608082)
53. AM Huber, et al. 2001 Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group J Rheumatol 28 5 1106 1111 11361197 1:STN:280:DC%2BD3M3nsVSjtg%3D%3D (Pubitemid 32422597)
54. LG Rider, et al. 2009 Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index Arthritis Rheum 60 11 3425 3435 19877055 10.1002/art.24904 This study validated the MDI in juvenile and adult myositis, described the degree and types of damage, and developed predictors of damage. Damage was found to be common in myositis after a median duration of 5 years in patients with adult-onset disease and 6.8 years in patients with juvenile-onset disease. The MDI has good content, construct, and predictive validity in juvenile and adult myositis
55. Ruperto, N. et al. The pediatric rheumatology international trials organization provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2010;62(11):1533-41. This study developed a provisional definition for the evaluation of response to therapy in JDM based on the PRINTO JDM core set of variables. The top definition of improvement was at least 20% improvement from baseline in three of six core set variables, with no more than one of the remaining worsening by more than 30% (which cannot be muscle strength).
56. E Stringer D Singh-Grewal BM Feldman 2008 Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features Arthritis Rheum 58 11 3585 3592 18975314 10.1002/art.23960
57. Ravelli, A. et al, Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1): p. 63-72. This study investigated the long-term outcome and prognostic factors of JDM through a multinational, multicenter study. Many patients had continued disease activity and cumulative damage at follow-up. A chronic course was the strongest predictor of poor prognosis. These findings highlight the need for treatment strategies that enable better control of disease activity over time and the reduction of nonreversible damage.
58. Sanner H, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: A case-control study. Arthritis Care Res (Hoboken). 2010;62(8):1103-11